Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gemcitabine-oxaliplatin plus rituximab (R-GEMOX) in refractory/relapsed patients with CD 20 positive diffuse large B-cell lymphoma [non-Hodgkin's lymphoma], non eligible for high-dose chemotherapy followed by autotransplantation.

Next Previous
X
Search
Trial Profile

Gemcitabine-oxaliplatin plus rituximab (R-GEMOX) in refractory/relapsed patients with CD 20 positive diffuse large B-cell lymphoma [non-Hodgkin's lymphoma], non eligible for high-dose chemotherapy followed by autotransplantation.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Rituximab (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms R-GEMOX

    • Most Recent Events

    • 26 Mar 2022 This trial has been completed in Belgium, according to European Clinical Trials Database record.
    • 01 Sep 2009 Sanofi-Synthelabo added as trial sponsor as reported by ClinicalTrials.gov.
    • 01 Sep 2009 Additional lead trial centres and trial investigator identified as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top